Evidence map›Paper›PMID 36605101›Full record

ArticleBioMed research international2022

The Emerging Role of Probiotics and their Derivatives against Biofilm-Producing MRSA: A Scoping Review.

Saba Jalalifar, Rasoul Mirzaei, Tahereh Motallebirad, Shabnam Razavi, Malihe Talebi

Open access · hybridAbstract readScoping Review
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Antagonistic Effects ofMicroorganisms · 2024
    Article
  7. Genomic insights fromFrontiers in microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Saba JalalifarMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-2243-5294
Rasoul MirzaeiVenom and Biotherapeutics Molecules Lab, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0002-4148-6495
Tahereh MotallebiradDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0003-3061-7987
Shabnam RazaviMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-4566-3089
Malihe TalebiMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-9111-8121
Iran University of Medical Sciences · IRIsfahan University of Medical Sciences · IRPasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methicillin-resistant Methods: Updated literature searches were conducted across seven electronic databases including Web of Science, PubMed, Scopus, Cochrane Library, ProQuest, Embase, and Google Scholar to identify all original published articles about probiotics against MRSA. In this regard, studies were summarized and analyzed in the present review. Results: In the reviewed studies, various microorganisms and compounds were used as probiotics as follows: Conclusions: Our study showed that there was an increasing trend in the number of publications reporting probiotics against biofilm-producing MRSA. The results of this scoping review could use to guide the undertaking of the subsequent systematic reviews. In summary, probiotics with antimicrobial and antibiofilm properties can use as an embedded agent in food products or as a biopharmaceutical in the prevention and treatment of MRSA infections.

Indexed as

Methicillin-Resistant Staphylococcus aureusProbioticsStaphylococcal InfectionsAnti-Bacterial AgentsBiofilmsHumansMicrobial Sensitivity TestsAnti-Bacterial Agents

Identifiers

PMID36605101
PMCPMC9810406
OpenAlexW4313250750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.